Germany

12 Vaccines Approved for Use in Germany

Protein Subunit

Novavax

Nuvaxovid

Approved in 40 countries
22 trials in 14 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax

Approved in 88 countries
70 trials in 24 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty

Approved in 149 countries
100 trials in 31 countries
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 149 countries
73 trials in 34 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax Bivalent Original/Omicron BA.1

Approved in 38 countries
5 trials in 4 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty Bivalent Original/Omicron BA.1

Approved in 35 countries
3 trials in 5 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty Bivalent Original/Omicron BA.4/BA.5

Approved in 33 countries
4 trials in 1 country
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Jcovden

Approved in 113 countries
26 trials in 25 countries
Approval Source: ema.europa.eu
Inactivated

Valneva

VLA2001

Approved in 33 countries
9 trials in 4 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax Bivalent Original/Omicron BA.4/BA.5

Approved in 33 countries
2 trials in 1 country
Approval Source: ema.europa.eu
Protein Subunit

Sanofi/GSK

VidPrevtyn Beta

Approved in 30 countries
3 trials in 2 countries
Approval Source: ema.europa.eu

19 in Clinical Trials in Germany

Protein Subunit

Clover

SCB-2019

15 trials in 13 countries
RNA

Pfizer/BioNTech

BNT162b1

5 trials in 3 countries
RNA

Pfizer/BioNTech

BNT162b2s01

3 trials in 2 countries
RNA

Pfizer/BioNTech

Comirnaty

Approved in 149 countries
100 trials in 31 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Non Replicating Viral Vector

ReiThera

GRAd-COV2

5 trials in 12 countries
Protein Subunit

Tuebingen

CoVac-1

3 trials in 1 country
VLP

Radboud University

ABNCoV2

4 trials in 3 countries
RNA

Pfizer/BioNTech

BNT162a1

2 trials in 1 country
RNA

Pfizer/BioNTech

BNT162b2 (B.1.1.7 + B.1.617.2)

RNA

Pfizer/BioNTech

BNT162b2 (B.1.1.7)

RNA

Pfizer/BioNTech

BNT162b2 (B.1.617.2)

RNA

Pfizer/BioNTech

BNT162b3

2 trials in 1 country
RNA

Pfizer/BioNTech

BNT162c2

2 trials in 1 country
Non Replicating Viral Vector

Universitätsklinikum Hamburg-Eppendorf

MVA-SARS-2-ST

3 trials in 1 country
Non Replicating Viral Vector

Universitatsklinikum Hamburg-Eppendorf

MVA-SARS-2-S

RNA

Pfizer/BioNTech

Comirnaty Bivalent Original/Omicron BA.1

Approved in 35 countries
3 trials in 5 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Jcovden

Approved in 113 countries
26 trials in 25 countries
Protein Subunit

Speransa Therapeutics

PRIME-2-CoV_Beta

1 Vaccines with Trials in Germany are No Longer Progressing

RNA

Curevac

CVnCoV

9 trials in 12 countries